• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi boasts observational hypoglycemia rates for Toujeo insulin injection

April 3, 2017 By Sarah Faulkner

Sanofi boasts observational hypoglycemia rates for Toujeo insulin injectionSanofi (NYSE:SNY) touted real-world clinical data for its Toujeo insulin glargine injection from a new observational study. The data from Deliver 2 showed that patients with Type II diabetes who switched to Toujeo from other basal insulins had significantly lower risk of hypoglycemia without compromising blood sugar control.

The Deliver 2 study analyzed electronic medical records for 1,894 patients in 2 matched cohorts, comparing changes to average blood sugar levels, as well as the rate of hypoglycemia and hypoglycemic events related to inpatient or emergency department visits in patients using Toujeo compared to other basal insulins.

After 6 months, patients who switched to Toujeo had 33% fewer hypoglycemic events compared to their cohorts, without compromising blood sugar control, Sanofi said. The company added that patients who switched to Toujeo had a 48% reduction in hypoglycemic events related to inpatient or emergency department encounters.

“These results increase the body of evidence on the use of Toujeo in people with Type II diabetes from observational studies. While randomized clinical trials provide the highest level of evidence, comparative data from real-world observational studies can be relevant for payors and other organizations evaluating how findings from clinical trials can translate into routine clinical practice,” Sanofi’s head of global diabetes Riccardo Perfetti said in prepared remarks. “Sanofi is committed to going beyond traditional models to conduct further studies to assess Toujeo, combining the broad populations, and type of interaction between healthcare professionals and patients seen in routine care with the rigorous methodology of clinical trials. The randomized Real Life Study program will provide further evidence that directly reflects Toujeo’s performance in standard clinical practice.”

Sanofi said it is conducting 3 randomized, real-life clinical studies with Toujeo, called Achieve Control, Reach Control and Regain Control. The studies enrolled more than 4,500 people with Type II diabetes who are starting basal insulin therapy or switching from a different basal insulin.

The researchers plan to collect patient feedback on treatment satisfaction, as well as clinical measures. The company expects initial results later this year, Sanofi reported.

Filed Under: Clinical Trials, Diabetes, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Sanofi-Aventis

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS